CD274 and non-small cell lung carcinoma: Immune check point inhibitors pembrolizumab, atezolizumab, or cemiplimab can be used as first-line single-agent for metastasized non-small cell lung cancer (NSCLC) patients with PD-L1 expression level ≥50% and negative driver gene mutation that have recommended first-line targeted therapy according to the NCCN guideline (17).